Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Ruining Zhang, Qingxing Xie, Xi Lu, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 10

Showing 10 citing articles:

Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 43
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
Elena Y. Rykova, Vadim V. Klimontov, Elena Kazakova, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1670-1670
Open Access | Times Cited: 1
Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer’s disease in type 2 diabetes
Prakash Ramakrishan, Jayaraman Rajangam, Shaheedha Shabudeen Mahinoor, et al.
Metabolic Brain Disease (2025) Vol. 40, Iss. 3
Closed Access
Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients
Huai Heng Loh, Siow Phing Tay, Ai Jiun Koa, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis
Xingyu Fan, Yueyue Wang, Yue Wang, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
The real-world anti-inflammatory effect of SGLT2i in patients with chronic heart failure
Alexandru Mircea Arvunescu, Ruxandra Florentina Ionescu, Silviu Ionel Dumitrescu, et al.
Journal of Medicine and Life (2025) Vol. 18, Iss. 2, pp. 155-164
Open Access
Endothelial Dysfunction and Cardiovascular Disease: Hyperbaric Oxygen Therapy as an Emerging Therapeutic Modality?
Tanja Batinac, Lara Batičić, Antea Kršek, et al.
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 12, pp. 408-408
Open Access | Times Cited: 2
SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my!
Brian F. Mandell
Cleveland Clinic Journal of Medicine (2024) Vol. 91, Iss. 7, pp. 392-393
Open Access
Latest Trends of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-i) for Heart Failure (HF) and Chronic Kidney Disease (CKD)
Hiroshi Bando
(2024) Vol. 1, Iss. 1, pp. 5-8
Closed Access
Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: a retrospective case series.
Tania Sundra, Edd Knowles, David Rendle, et al.
Domestic Animal Endocrinology (2024) Vol. 90, pp. 106894-106894
Open Access
Page 1

Scroll to top